Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study

David Price; Maarten j. h. i. Beekman; Walter javier Mattarucco; Rocio martina Barriga-Acevedo; Hao-Chien Wang; Dina v. Diaz; Adel Khattab; Manuel Pacheco gallego; Ashraf Al zaabi; Hisham Farouk; Darush Attar-Zadeh

doi:10.1038/s41533-024-00397-4

Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study

David Price, Maarten j. h. i. Beekman^* (Corresponding Author), Walter javier Mattarucco, Rocio martina Barriga-Acevedo, Hao-Chien Wang, Dina v. Diaz, Adel Khattab, Manuel Pacheco gallego, Ashraf Al zaabi, Hisham Farouk, Darush Attar-Zadeh

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Downloads (Pure)

Abstract

This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48.9 years). Of the 2810 patients prescribed ≥3 SABA canisters, 776 (27.6%) also purchased ≥1 SABA OTC. This subset of 776 patients reported the highest disease burden; 73.2% had ≥1 severe exacerbation and 55.7% had uncontrolled asthma. Asthma-related outcomes worsened with any SABA OTC purchase, regardless of SABA prescriptions; disease burden was the highest in patients with ≥3 SABA prescriptions and ≥1 SABA OTC purchase vs 1–2 SABA prescriptions only (86% lower odds of having at least partly controlled asthma and 124% increased incidence of severe asthma (both P < 0.001). These findings emphasize the need to implement policy changes to restrict SABA purchase without prescriptions and ensure access to affordable asthma care.

Original language	English
Article number	34
Number of pages	10
Journal	npj Primary Care Respiratory Medicine
Volume	34
Issue number	1
Early online date	1 Nov 2024
DOIs	https://doi.org/10.1038/s41533-024-00397-4
Publication status	Published - 1 Nov 2024

Bibliographical note

Acknowledgements
AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study, and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided by Praveen Kaul, PhD, of Cactus Life Sciences (part of Cactus Communications), Mumbai, India, in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460) and fully funded by AstraZeneca.

Keywords

asthma
health policy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s41533-024-00397-4Licence: CC BY-NC-ND

Price_etal_NPJPCRM_Over_The_Counter_VoR
This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Final published version, 1.55 MBLicence: CC BY-NC-ND

Cite this

Price, D., Beekman, M. J. H. I., Mattarucco, W. J., Barriga-Acevedo, R. M., Wang, H.-C., Diaz, D. V., Khattab, A., Pacheco gallego, M., Al zaabi, A., Farouk, H., & Attar-Zadeh, D. (2024). Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study. npj Primary Care Respiratory Medicine, 34(1), Article 34. https://doi.org/10.1038/s41533-024-00397-4

Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study. / Price, David; Beekman, Maarten j. h. i. (Corresponding Author); Mattarucco, Walter javier et al.
In: npj Primary Care Respiratory Medicine, Vol. 34, No. 1, 34, 01.11.2024.

Research output: Contribution to journal › Article › peer-review

Price, D, Beekman, MJHI, Mattarucco, WJ, Barriga-Acevedo, RM, Wang, H-C, Diaz, DV, Khattab, A, Pacheco gallego, M, Al zaabi, A, Farouk, H & Attar-Zadeh, D 2024, 'Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study', npj Primary Care Respiratory Medicine, vol. 34, no. 1, 34. https://doi.org/10.1038/s41533-024-00397-4

@article{2ffa01ede473450a9b7d46d61054edcd,

title = "Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study",

abstract = "This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48.9 years). Of the 2810 patients prescribed ≥3 SABA canisters, 776 (27.6%) also purchased ≥1 SABA OTC. This subset of 776 patients reported the highest disease burden; 73.2% had ≥1 severe exacerbation and 55.7% had uncontrolled asthma. Asthma-related outcomes worsened with any SABA OTC purchase, regardless of SABA prescriptions; disease burden was the highest in patients with ≥3 SABA prescriptions and ≥1 SABA OTC purchase vs 1–2 SABA prescriptions only (86% lower odds of having at least partly controlled asthma and 124% increased incidence of severe asthma (both P < 0.001). These findings emphasize the need to implement policy changes to restrict SABA purchase without prescriptions and ensure access to affordable asthma care.",

keywords = "asthma, health policy",

author = "David Price and Beekman, {Maarten j. h. i.} and Mattarucco, {Walter javier} and Barriga-Acevedo, {Rocio martina} and Hao-Chien Wang and Diaz, {Dina v.} and Adel Khattab and {Pacheco gallego}, Manuel and {Al zaabi}, Ashraf and Hisham Farouk and Darush Attar-Zadeh",

note = "Acknowledgements AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study, and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided by Praveen Kaul, PhD, of Cactus Life Sciences (part of Cactus Communications), Mumbai, India, in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460) and fully funded by AstraZeneca.",

year = "2024",

month = nov,

day = "1",

doi = "10.1038/s41533-024-00397-4",

language = "English",

volume = "34",

journal = "npj Primary Care Respiratory Medicine",

issn = "2055-1010",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes

T2 - a post hoc analysis of the SABINA III study

AU - Price, David

AU - Beekman, Maarten j. h. i.

AU - Mattarucco, Walter javier

AU - Barriga-Acevedo, Rocio martina

AU - Wang, Hao-Chien

AU - Diaz, Dina v.

AU - Khattab, Adel

AU - Pacheco gallego, Manuel

AU - Al zaabi, Ashraf

AU - Farouk, Hisham

AU - Attar-Zadeh, Darush

N1 - Acknowledgements AstraZeneca funded all the SABINA studies and was involved in designing the study, developing the study protocol, conducting the study, and performing the analyses. AstraZeneca was given the opportunity to review the manuscript before submission and funded medical writing support. Writing and editorial support was provided by Praveen Kaul, PhD, of Cactus Life Sciences (part of Cactus Communications), Mumbai, India, in accordance with Good Publication Practice (GPP 2022) guidelines (https://www.acpjournals.org/doi/10.7326/M22-1460) and fully funded by AstraZeneca.

PY - 2024/11/1

Y1 - 2024/11/1

N2 - This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48.9 years). Of the 2810 patients prescribed ≥3 SABA canisters, 776 (27.6%) also purchased ≥1 SABA OTC. This subset of 776 patients reported the highest disease burden; 73.2% had ≥1 severe exacerbation and 55.7% had uncontrolled asthma. Asthma-related outcomes worsened with any SABA OTC purchase, regardless of SABA prescriptions; disease burden was the highest in patients with ≥3 SABA prescriptions and ≥1 SABA OTC purchase vs 1–2 SABA prescriptions only (86% lower odds of having at least partly controlled asthma and 124% increased incidence of severe asthma (both P < 0.001). These findings emphasize the need to implement policy changes to restrict SABA purchase without prescriptions and ensure access to affordable asthma care.

AB - This post-hoc analysis of the SABINA III study evaluated the association of short-acting β2-agonist (SABA) prescriptions and self-reported over-the-counter (OTC) SABA purchase in the previous 12 months with asthma-related outcomes using multivariable regression models in 4556 patients (mean age, 48.9 years). Of the 2810 patients prescribed ≥3 SABA canisters, 776 (27.6%) also purchased ≥1 SABA OTC. This subset of 776 patients reported the highest disease burden; 73.2% had ≥1 severe exacerbation and 55.7% had uncontrolled asthma. Asthma-related outcomes worsened with any SABA OTC purchase, regardless of SABA prescriptions; disease burden was the highest in patients with ≥3 SABA prescriptions and ≥1 SABA OTC purchase vs 1–2 SABA prescriptions only (86% lower odds of having at least partly controlled asthma and 124% increased incidence of severe asthma (both P < 0.001). These findings emphasize the need to implement policy changes to restrict SABA purchase without prescriptions and ensure access to affordable asthma care.

KW - asthma

KW - health policy

U2 - 10.1038/s41533-024-00397-4

DO - 10.1038/s41533-024-00397-4

M3 - Article

SN - 2055-1010

VL - 34

JO - npj Primary Care Respiratory Medicine

JF - npj Primary Care Respiratory Medicine

IS - 1

M1 - 34

ER -

Over-the-counter short-acting β2-agonist purchase and asthma-related health outcomes: a post hoc analysis of the SABINA III study

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this